Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KYAT1 | Q16773 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020745 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPK1TSHRFABP4LMNA | |
| SCHEMBL4019783 | 0.88 | MAPK1 (0.41) | SMN1; SMN2MAPK1TSHRLMNAMAPT | |
| SCHEMBL1852856 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPK1TSHRLMNAMAPT | |
| SCHEMBL1852104 | 0.83 | KMT2A (0.50) | SMN1; SMN2MAPK1TSHRFABP4LMNA | |
| SCHEMBL1857604 | 0.76 | CASR (0.40) | SMN1; SMN2TSHRLMNAMAPTMEN1 | |
| SCHEMBL5047516 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1TSHRLMNAMAPT | |
| SCHEMBL4024326 | 0.76 | MAPK1 (0.46) | SMN1; SMN2MAPK1TSHRLMNA | |
| SCHEMBL1855560 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPK1TSHRMEN1HTT | |
| SCHEMBL1854510 | 0.75 | LPAR1 (0.45) | AKR1C3 | |
| SCHEMBL4021417 | 0.75 | LIMK2 (0.39) | SMN1; SMN2TSHRLMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | claimed |
| EP-1986637-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | Laboratoires Serono SA (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093557-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | LABORATOIRES SERONO S.A. (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | STS, TST, SULT1A1 | SMN1; SMN2 2147/4885KYAT1 1447/4885MAPK1 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.